FDA nod for Aurobindo's acid reflux treatment drug

Aurobindo Pharma receives the US health regulator's approval for Famotidine Tablets


The approved ANDA is bioequivalent to Valeant Pharmaceuticals's Pepcid Tablets

Aurobindo Pharma announces that the company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Famotidine Tablets USP, 20 mg and 40 mg.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Pepcid Tablets, 20 mg and 40 mg, of Valeant Pharmaceuticals International.

Famotidine Tablets is used for the short-term treatment of gastroesophageal reflux disease and active duodenal ulcer. The approved product has an estimated market size of $29 million for the twelve months ending October 2015 according to IMS.



Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email